{"entity":{"id":"virogin-biotech","kind":"company","name":"Virogin Biotech","aka":["Virogin Biotech Ltd.","Virogin Biotech Canada Ltd","CNBG-Virogin Biotech (Shanghai) Ltd.","Shanghai Virogin Biotech Co., Ltd."],"tldr":"Virogin Biotech makes oncolytic viruses: modified herpes viruses that infect and break open cancer cells and alert the immune system. Its medicines are in trials in liver and bile duct cancers and other advanced solid tumours.","summary":"Virogin Biotech describes itself as a clinical-stage immuno-oncology company combining oncolytic virotherapy with mRNA vaccines in a prime-boost approach; it states it was founded in Canada in 2015 and lists offices in Richmond, British Columbia, and Shanghai. Its registered programmes include VG161, studied since 2021 by its Shanghai affiliate in advanced solid tumours, primary liver cancer, sarcoma and intrahepatic cholangiocarcinoma, and VG2025, a recombinant human IL-12/IL-15 dual-regulated oncolytic HSV-1. Under the sponsor name Virogin Biotech Ltd. it registered a phase 2 trial of VG2025 in intrahepatic cholangiocarcinoma (NCT07522476, posted April 2026) and a phase 1/2 trial of intravenous VG2025 in advanced solid tumours (NCT07682870). Its first registered cancer trial under any Virogin sponsor name, NCT04758897 (VG161 in advanced solid tumours, sponsored by CNBG-Virogin Biotech (Shanghai) Ltd.), was posted on ClinicalTrials.gov in February 2021.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.virogin.com/"},{"label":"About Virogin","url":"https://virogin.com/about/"},{"label":"ClinicalTrials.gov: phase 2 trial of VG2025 in intrahepatic cholangiocarcinoma (NCT07522476)","url":"https://clinicaltrials.gov/study/NCT07522476"},{"label":"ClinicalTrials.gov: phase 1/2 trial of intravenous VG2025 (NCT07682870)","url":"https://clinicaltrials.gov/study/NCT07682870"},{"label":"ClinicalTrials.gov: VG161 in advanced solid tumours (NCT04758897)","url":"https://clinicaltrials.gov/study/NCT04758897"}],"tags":[],"related":[],"cancers":["intrahepatic-cholangiocarcinoma","cholangiocarcinoma","hcc"],"sections":["immunotherapy"],"technologies":["oncolytic-virus"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Headquarters not named on the website; Richmond, British Columbia is the Canadian office it lists, and the company says it was founded in Canada.","Founding year from the company's About page ('Founded in Canada in 2015'). The website does not say which office is the headquarters.","The registry search flagged Virogin Biotech Ltd. as a new sponsor in 2026, but related Virogin entities registered cancer trials from 2021, so this is not a new clinical entrant.","Financing not stated on the pages read. The website does not describe VG161 or VG2025; programme details come from ClinicalTrials.gov records read on 29 October 2026.","Akeso also sponsors a trial combining its AK112 with VG2025 (NCT07357220)."],"hq":"Richmond, BC","country":"CA","companyType":"biotech","website":"https://www.virogin.com/","founded":2015,"stage":"growth","investors":[],"funding":[]},"route":"/companies/virogin-biotech/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"intrahepatic-cholangiocarcinoma","kind":"cancer","name":"Intrahepatic cholangiocarcinoma","route":"/cancers/intrahepatic-cholangiocarcinoma/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/"}]}}